Mipletamig Triplet Produces Early Responses in TP53-Mutated Frontline AML
Aptevo reported that 13 of 14 evaluable, newly diagnosed patients with TP53-mutated acute myeloid leukemia derived a protocol-defined clinical benefit from mipletamig plus venetoclax and azacitidine. Eleven patients achieved complete remission or complete remission…
